CAJ | 학술논문

随着对三阴性乳腺癌( TNBC)分子生物学特征的深入研究，越来越多的潜在治疗靶点及药物也逐渐应用于临床，如以olaparib、veliparib等为代表的DNA损伤修复阻断剂、表皮生长因子受体为靶点的单克隆抗体西妥昔单抗、抗血管生成抑制剂贝伐单抗等使TNBC获益。临床需继续开展肿瘤科与分子生物学等学科的交叉研究，并深入对已有研究成果的安全性和有效性进行验证，为TNBC的临床治疗提供新的希望。
수착대삼음성유선암( TNBC)분자생물학특정적심입연구，월래월다적잠재치료파점급약물야축점응용우림상，여이olaparib、veliparib등위대표적DNA손상수복조단제、표피생장인자수체위파점적단극륭항체서타석단항、항혈관생성억제제패벌단항등사TNBC획익。림상수계속개전종류과여분자생물학등학과적교차연구，병심입대이유연구성과적안전성화유효성진행험증，위TNBC적림상치료제공신적희망。
With the in-depth study of the molecular biological characteristics of triple-negative breast cancer( TNBC) ,more and more potential therapeutic targets and drugs are also increasingly used in the clini-cal treatment. The olaparib,veliparib as the representative of DNA damage repair blockers,monoclonal anti-body cetuximab targeting epidermal growth factor receptor,and anti-angiogenesis inhibitor bevacizumab make TNBC beneficialOncology and molecular biology cross-disciplinary research should be continued in clinical, and the depth study of the safety and effectiveness of existing research should be done for validation,in order to provide new hope for the clinical treatment of TNBC.